ASH 2022 | Pilot study of prophylactic anakinra to mitigate CAR-T-related neurotoxicity in R/R LBCL
Neurotoxicity is a key side effect of the CAR-T therapy axicabtagene ciloleucel (axi-cel). Preclinical data has suggested that the IL-1-targeting anakinra can help prevent neurotoxicity. Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses primary analysis results from a pilot study (NCT04432506) of prophylactic anakinra, aiming to mitigate CAR-T associated neurotoxicity in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Dr Strati explains the study design of this trial and reports that the use of anakinra reduced neurotoxicity by approximately 50%. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Hutchinson MediPharma: Consultancy; ADC Therapeutics: Consultancy, Research Funding; TG Therapeutics: Consultancy; Kite Gilead: Consultancy; Astrazeneca Acerta: Research Funding; ALX Oncology: Research Funding; Sobi: Research Funding; Roche Genentech: Consultancy.
